I agree with Respert, buttoning down the CRC proto
Post# of 145747
![](/assets/46931549/no_avatar_available_thumb.jpg)
1) Wow, what a broad suite of indications…cancer…multiple types!
2) Inflammation…again, multiple origins? Strong hints of platform molecule. Alzheimer’s!
3) Multiple trials already phase 2 and a successful trial from phase 3?!
4) Leronlimab to PREVENT AND/OR REVERSE liver inflammation. Preclinical, but the MASH mice, those still squeaking at the end of the study this September under the influence of Leronlimab have the potential to catapult direct to phase 2 under a partnership. If so, current share prices should be in the rear-view mirror. Remind yourself Cytodyn has already completed a phase 2 study for MASH in humans…this is a very high probability event IMHO. While preclinical I expect this study will kick it in like Hocker did to win gold in Olympic record time to astonish the front runners in the men’s 1500 meter run.
Marketing 101 puts your cherished jewel first…Cytodyn is going after cancer in a big way. I am reminded of Scott Kelly’s comment: “I think we will be known as an oncology company.”
Cancer lanes in blue, inflammation in red…mix them together and you have purple…Tyrolian purple dye was the most cherished and expensive in the ancient world, reserved strictly for royal wealth and privilege. In due course Leronlimab will be clothed in the same awe.
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)